Baidu
map

上海肿瘤领域**奖项颁奖 凸显肿瘤诊治精准化及全程精细化管理

2020-10-01 陈静 汤佳贞 中国新闻网

第五届上海市抗癌科技奖30日颁奖。12个项目获奖展示了近年来上海市肿瘤诊治研究的大方向和新高度。

第五届上海市抗癌科技奖30日颁奖。12个项目获奖展示了近年来上海市肿瘤诊治研究的大方向和新高度。

上海市抗癌协会方面30日对记者表示,这些获奖项目强调了肿瘤诊治精准化及全程精细化管理,在多学科的协同合作下共同解决诊疗难题,并将学术成果转化为临床能量,改善患者的预后和生存。

据悉,上海市抗癌科技奖是上海肿瘤领域的最高奖项,获奖项目组对于不同肿瘤领域难点,从基础研究、策略建立到成果推广,展现了上海市各大医疗机构研究团队在推动肿瘤精准化的诊断治疗及管理中迈出的步伐。上海市抗癌协会将积极把上海肿瘤诊治方面的创新成果推向全国。

据了解,上海复旦大学附属肿瘤医院的邵志敏教授和上海市肺科医院的陈昶教授主持的项目荣获此次抗癌科技奖一等奖。邵志敏教授主持的研究项目聚焦乳腺癌中恶性程度最高、预后最差的三阴性乳腺癌,绘制中国人群三阴性乳腺癌多组学图谱;确立三阴性乳腺癌优选化疗方案,揭示逆转化疗耐药新策略。邵志敏教授团队还准确预测三阴性乳腺癌复发转移风险,揭示新的治疗靶点。

肺癌是发病率、致死率最高的癌症。早期肺癌的筛查、手术决策、复发高危人群识别及辅助治疗都是个体化诊治难点。基于此,陈昶教授团队持续科研攻关,从术前、术中、术后多节点开展系列研究。其团队革新肺癌筛查策略和术前影像诊断体系。研究人员自主研发两项肺癌早筛液体活检产品;建立早期肺癌人工智能影像诊断系统,使早期肺癌检出率提升15.8%。他们还完善早期肺癌微创手术规范。

上海市抗癌协会理事长、复旦大学附属肿瘤医院副院长陈震教授接受采访时表示,作为中国抗癌科技奖乃至更高奖项的蓄水池,上海市抗癌科技奖鼓励更多抗癌一线的肿瘤研究者不断改革创新,优化诊疗,将高质量的项目推向中国甚至世界舞台。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028202, encodeId=7135202820209, content=<a href='/topic/show?id=2e39e65970b' target=_blank style='color:#2F92EE;'>#精细化管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76597, encryptionId=2e39e65970b, topicName=精细化管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed May 05 11:44:37 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004334, encodeId=608a2004334e8, content=<a href='/topic/show?id=27cde6356a1' target=_blank style='color:#2F92EE;'>#精准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76356, encryptionId=27cde6356a1, topicName=精准化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 03 09:44:37 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971252, encodeId=110419e125250, content=<a href='/topic/show?id=3f2ce6594e4' target=_blank style='color:#2F92EE;'>#精细化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76594, encryptionId=3f2ce6594e4, topicName=精细化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Sun Nov 22 15:44:37 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069883, encodeId=16d8206988377, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Mon Feb 22 00:44:37 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403529, encodeId=a1441403529d5, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 03 14:44:37 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028202, encodeId=7135202820209, content=<a href='/topic/show?id=2e39e65970b' target=_blank style='color:#2F92EE;'>#精细化管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76597, encryptionId=2e39e65970b, topicName=精细化管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed May 05 11:44:37 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004334, encodeId=608a2004334e8, content=<a href='/topic/show?id=27cde6356a1' target=_blank style='color:#2F92EE;'>#精准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76356, encryptionId=27cde6356a1, topicName=精准化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 03 09:44:37 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971252, encodeId=110419e125250, content=<a href='/topic/show?id=3f2ce6594e4' target=_blank style='color:#2F92EE;'>#精细化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76594, encryptionId=3f2ce6594e4, topicName=精细化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Sun Nov 22 15:44:37 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069883, encodeId=16d8206988377, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Mon Feb 22 00:44:37 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403529, encodeId=a1441403529d5, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 03 14:44:37 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028202, encodeId=7135202820209, content=<a href='/topic/show?id=2e39e65970b' target=_blank style='color:#2F92EE;'>#精细化管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76597, encryptionId=2e39e65970b, topicName=精细化管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed May 05 11:44:37 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004334, encodeId=608a2004334e8, content=<a href='/topic/show?id=27cde6356a1' target=_blank style='color:#2F92EE;'>#精准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76356, encryptionId=27cde6356a1, topicName=精准化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 03 09:44:37 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971252, encodeId=110419e125250, content=<a href='/topic/show?id=3f2ce6594e4' target=_blank style='color:#2F92EE;'>#精细化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76594, encryptionId=3f2ce6594e4, topicName=精细化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Sun Nov 22 15:44:37 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069883, encodeId=16d8206988377, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Mon Feb 22 00:44:37 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403529, encodeId=a1441403529d5, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 03 14:44:37 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2028202, encodeId=7135202820209, content=<a href='/topic/show?id=2e39e65970b' target=_blank style='color:#2F92EE;'>#精细化管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76597, encryptionId=2e39e65970b, topicName=精细化管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed May 05 11:44:37 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004334, encodeId=608a2004334e8, content=<a href='/topic/show?id=27cde6356a1' target=_blank style='color:#2F92EE;'>#精准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76356, encryptionId=27cde6356a1, topicName=精准化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 03 09:44:37 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971252, encodeId=110419e125250, content=<a href='/topic/show?id=3f2ce6594e4' target=_blank style='color:#2F92EE;'>#精细化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76594, encryptionId=3f2ce6594e4, topicName=精细化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Sun Nov 22 15:44:37 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069883, encodeId=16d8206988377, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Mon Feb 22 00:44:37 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403529, encodeId=a1441403529d5, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 03 14:44:37 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2028202, encodeId=7135202820209, content=<a href='/topic/show?id=2e39e65970b' target=_blank style='color:#2F92EE;'>#精细化管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76597, encryptionId=2e39e65970b, topicName=精细化管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed May 05 11:44:37 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004334, encodeId=608a2004334e8, content=<a href='/topic/show?id=27cde6356a1' target=_blank style='color:#2F92EE;'>#精准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76356, encryptionId=27cde6356a1, topicName=精准化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 03 09:44:37 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971252, encodeId=110419e125250, content=<a href='/topic/show?id=3f2ce6594e4' target=_blank style='color:#2F92EE;'>#精细化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76594, encryptionId=3f2ce6594e4, topicName=精细化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffd5416, createdName=bettycmoon, createdTime=Sun Nov 22 15:44:37 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069883, encodeId=16d8206988377, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Mon Feb 22 00:44:37 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403529, encodeId=a1441403529d5, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Oct 03 14:44:37 CST 2020, time=2020-10-03, status=1, ipAttribution=)]

相关资讯

安宁疗护的“上海模式”:年内各区建设至少1家区级安宁疗护中心

日前(6月1日),上海卫健委官网发布《关于推进2020年本市安宁疗护试点工作的通知》(下简称“通知”),通知指出,今年年内,要实现所有社区卫生服务中心均开展病房或居家安宁疗护服

怎样让临终患者有尊严地接受疗护?上海有了新规定!

日前,上海市卫健委官网根据《关于印发安宁疗护中心基本标准(试行)和安宁疗护中心管理规范(试行)》(国卫医发〔2017〕7号)、《安宁疗护实践指南(试行)》(国卫办医发〔2017〕5号),结合上海市实际

新冠病毒中和抗体临床试验在上海启动

日前,上海君实生物医药科技股份有限公司与中国科学院微生物研究所等单位共同开发的重组全人源抗新冠病毒单克隆抗体注射液(以下简称“JS016”)获得国家药监局批准,进入Ⅰ期临床试验

岳阳医院在全国三级公立中西医结合医院绩效考核中排名**

7月1日,国家卫健委发布了《2018年度全国三级公立医院绩效考核国家监测分析有关情况的通报》,这也是首次全国三级公立医院绩效考核亮出成绩单!上海中医药大学附属岳阳中西医结合医院名列全国三级公立中西医结

上海医保监管新规实施 打击欺诈骗保还需“内外兼修”

上海医保监管新规——《上海市基本医疗保险监督管理办法》即将于6月1日起正式施行,此后欺诈骗保等违法违规行为的法律责任更加清晰,惩罚力度将不断加强。

Baidu
map
Baidu
map
Baidu
map